DoW Phase II Award Accelerates RTAD Platform for Cold-Chain-Free Delivery of Biologics to the Defense Operators
PRINCETON, NEW JERSEY – April 12, 2026 – Inaedis, Inc. is proud to announce it has been awarded a Phase II Small Business Innovation Research (SBIR) contract award from the U.S. Department of War (DoW) to accelerate development of its proprietary Rapid Room-Temperature Aerosol Dehydration (RTAD) platform for the thermal stabilization and self-administered delivery of heat-sensitive medical countermeasures (MCMs).
This Phase II award builds directly on Inaedis’ successful Phase I SBIR project, in which the company demonstrated the foundational feasibility of RTAD platform for thermostabilizing heat-sensitive MCM biologics. With Phase II funding, Inaedis will now advance three major technical objectives:
- Monoclonal Antibody (mAb) Stabilization and Self-Administration: Developing ultra-concentrated RTAD-formulated mAb drug products for subcutaneous or intramuscular self-administration.
- Inhaled Formulations of Nucleic Acids: Formulating a broad-spectrum anti-viral prophylactic nucleic acids as inhaled shelf-stable dry powders to enable field protection.
- Pilot-Scale Manufacturing: Scaling RTAD production capacity up to pilot-scale within a cGMP-compliant pharmaceutical spray drying facility, and defining the regulatory and commercial roadmap.
Technology Impact and Defense Application
RTAD converts fragile liquid biologics into room-temperature-stable dry powder formulations without heat or freezing — directly addressing the DoW’s critical need for reliable medical countermeasure deployment in austere, forward-deployed environments. The platform eliminates cold chain dependence, reduces logistical burden, and enables novel self-administered routes such as inhaled powders and ultra-concentrated injectable suspensions.
Leadership Statement
“This Phase II award from the DoW is a major validation of our RTAD platform and a pivotal step for Inaedis,” said Dr. Maksim Mezhericher, Founder and CEO of Inaedis. “Following the successful Phase I work, we are now positioned to deliver tangible, mission-ready solutions: biologics and medical countermeasures that are thermally stable, self-administrable, and deployable anywhere without refrigeration. This is a breakthrough for warfighter readiness and a transformative step for global healthcare.”